Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B‐Cell Lymphoma and Follicular Lymphoma
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 21.04.2026. Verfasst von Lulu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Neoplasms, Second Primary. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Secondary primary solid malignancies (SPSMs) significantly impact long‐term outcomes in lymphoma patients. However, subtype‐specific differences remain unclear, such as diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL).
Methods
This study collected 1,377 DLBCL and 489 FL patients, identifying 50 DLBCL and 31 FL cases with SPSMs. Clinical characteristics, SPSM types, and survival were compared in these 81 patients. Demographic, clinical, treatment‐related variables (including radiotherapy for primary lymphoma, recorded as yes/no), and survival outcomes were collected. Overall survival (OS) was analyzed using Kaplan–Meier estimates and Cox proportional hazards models. The cumulative incidence of SPSMs was evaluated with competing risk analysis (death as a competing event), and group comparisons were performed with Gray's test. Prognostic factors identified in univariable analysis ( p < 0.05) were included in a multivariable Cox model. A nomogram was developed, with discriminative ability assessed by the area under the receiver operating characteristic curve (ROC). Statistical significance was set at p < 0.05.
Results
SPSMs were observed more frequently in FL (6.34%) than DLBCL (3.63%). Thyroid cancer predominated (22.2%, 18/81). DLBCL patients developed SPSMs earlier than FL patients (median 28.47 vs. 41.77 months, p = 0.031), though cumulative incidence accounting for competing risks did not differ significantly (Gray's test p = 0.34). DLBCL patients with SPSMs had inferior OS compared to FL patients ( p = 0.04). Non‐GCB DLBCL showed greater SPSM diversity and survival disadvantage. Multivariable analysis identified FL (vs. DLBCL) subtype (HR = 0.328, p = 0.018), bone marrow infiltration (HR = 2.815, p = 0.014), initial radiotherapy before SPSM diagnosis (HR = 3.475, p = 0.005), and shorter time to SPSM development (HR = 0.973 per month, p = 0.021) as independent prognostic factors for worse OS. The nomogram model showed acceptable discrimination, with an AUC of 0.761 in the time‐dependent ROC analysis.
Conclusion
This study provides novel insights into SPSM characteristics and prognostic differences in DLBCL and FL patients within a Chinese cohort. SPSMs in FL patients were observed more frequently, while DLBCL patients, particularly those with non‐GCB subtypes, experience earlier SPSM onset and poorer survival. The validated nomogram, incorporating lymphoma‐related factors, enables personalized risk stratification. However, the single‐center design, small sample size ( n = 81), and lack of SPSM‐specific data limit generalizability, necessitating multi‐center studies with comprehensive SPSM characterization for validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
- Department of Neurosurgery/Neuro-Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Lulu Zhang
Zitieren
APA
Zhang, L., Tian, J., Xiong, Q., Ye, H., Wang, Z., Wang, Y., Guo, C., & Huang, H. (2026). Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B‐Cell Lymphoma and Follicular Lymphoma. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71844
Vancouver
Zhang L, Tian J, Xiong Q, Ye H, Wang Z, Wang Y, et al. Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B‐Cell Lymphoma and Follicular Lymphoma. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71844
BibTeX
@article{Zhang2026,
author = {Zhang, Lulu and Tian, Jiahao and Xiong, Qunli and Ye, Haimei and Wang, Zhao and Wang, Yu and Guo, Chengcheng and Huang, He},
title = {Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B‐Cell Lymphoma and Follicular Lymphoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71844}
}
EUVIMED